RENGEVITY-201 Trial: Pegrizeprument Takes On Tacrolimus
Witfire Elite | Clinical Catalysts | Trial Design Audit RENGEVITY-201 trial dosing has begun, Veloxis says, with the first participant now treated. The Phase…
Read the analysis → 01 / Intelligence
Latest Pharma Intelligence
Decision-useful coverage for executives, investors, regulators and scientists.
PULSE-LHD Trial Enrols First U.S. Patients
Witfire Elite · Clinical Catalysts · Trial Design Audit Pulnovo says two U.S. participants have undergone PULSE-LHD procedures at Henry Ford. The registry estimates…
Ravulizumab ARTEMIS: 555 Patients, Six Terminations, and a Mechanism That Did Not Travel
Witfire Elite · Clinical Catalysts · Registry Analysis The ravulizumab ARTEMIS trial has been terminated at 555 patients. Read alone it is one failed…
OX40 Atopic Dermatitis: A Drug Class Ended in 175 Days and 8,185 Patients
Witfire Elite · Clinical Catalysts · Registry Analysis OX40 atopic dermatitis development is over. Two companies, two mechanisms, 175 days. The press releases said…
Teva Q2 2026 Results: What the Numbers Actually Say
Teva's Q2 2026 revenue fell 1%, operating income fell $686M and the shares rose 8.6%. All three follow from one subtraction the release never performs: US generics lost $301M in the quarter, and three branded products added $306M.
J&J Talc Settlement: $5.5 Billion, 76,000 Claims and the 95% Condition
Witfire Elite · Litigation Risk Brief · Product Liability Johnson & Johnson won a causation ruling. One week later it settled anyway. Understanding why…
Novo Nordisk Eli Lilly Lawsuit: What the Case Turns On
Witfire Elite · Litigation Risk Brief · GLP-1 Series No. 04 Novo Nordisk vs Eli Lilly: The Obesity Ad War Neither Side Can Win…
02 / Breaking Analysis
Consequences, not headlines
Original analysis connecting scientific evidence, regulatory decisions and market value.
Sun Pharma Organon Deal: Why 2027 Decides Everything
Witfire Elite · M&A Risk Brief · Deal No. 2026-07 Sun Pharma’s $11.75B Organon Deal: Platform Acquisition or Debt-Heavy Scale Bet? Shareholders cleared the…
Oral PCSK9 Inhibitor Approved: LIPFENDRA Price vs Repatha
Witfire Elite · Cardiometabolic Risk Brief · Pricing & Access Oral PCSK9 Inhibitor Approved: LIPFENDRA Lists at $315. Repatha Already Sells for $239. The…
The Stabilizer Ceiling: What 3 Amyloidosis Trials Reveal
Witfire Elite · Trial Design & Strategy · Framework HELIOS-B vs CARDIO-TTRansform: What the Eplontersen Miss Reveals HELIOS-B cleared its endpoint. CARDIO-TTRansform missed. CARES…
03 / Coverage
The pharma decision map
Regulatory Radar
FDA & Regulatory Intelligence
Capital & Deals
Investments
Market Signals
Stock Market
- Teva Q2 2026 Results: What the Numbers Actually Say
- Eli Lilly Retatrutide Phase 3 Results at ADA 2026
- The Pharma Tariff War: How US Drug Pricing Pressure Is Forcing Big Pharma to Rewrite Global Strategy
- Pharma Stock Market News: US-Israel-Iran War Impact on Drug Companies, Oil Prices, and Pharma Supply Chains
Witfire Elite Pharma News
July 2026 · Vol. I, No. 2
Chokepoints & Catalysts
The monthly issueWitfire Elite Magazine
Where science meets strategy and breaks.
Witfire Elite Review, July 2026 -The Weakest Layer: The Stabilizer Ceiling, Eplontersen's CARDIO-TTRansform Miss, Unicycive OLC CRL.
Read the digital issue →